Protocol for the in-House Production of Cryoprecipitate

Ohishi, Kohshi; Matsumoto, Toshifumi; Tanaka, Yumi; Makino, Shigeyoshi; Tamaki, Shigehisa; Mori, Keiko; Fujimori, Yoshihiro; Ikemoto, Junko; Iwao, Noriaki; Kato, Hidefumi; Kino, Shuichi; Takeshita, Akira; Yamada, Chiaki; Fujii, Satoshi; Watanabe, Naoki; Otsuka, Kohei; Yamamoto, Kōji; Hoshino, Koji; Miyazaki, Kenichi; Maeda, Hitoshi; Miyata, Shigeki

doi:10.3925/jjtc.62.664

Cited by 10 publications

(10 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Standard method: In brief, one pack of CRYO was prepared from a bag of divided FFP (240 ml), and it was thawed at 2–6°C for 18 h. The bag was then centrifuged at 3180 g for 10 min (Large Capacity Refrigerated Centrifuge, Model 8730, KUBOTA, Tokyo, Japan), and the sediment (CRYO) was re‐suspended in 30–40 ml of plasma 1, 10 …”

Section: Methodsmentioning

confidence: 99%

See 1 more Smart Citation

A novel modified thaw‐siphon method for extracting cryoprecipitate: The Bokutoh‐siphon method

et al. 2021

View full text Add to dashboard Cite

Background Cryoprecipitate (CRYO) is neither produced nor supplied by the Japanese Red Cross Society. A novel CRYO extraction method established in‐house by modifying a thaw‐siphon technique was demonstrated in this study. Study Design and Methods A pack of fresh frozen plasma was thawed and equally divided into two bags for CRYO extraction by different methods. CRYO was extracted from the blood plasma using a standard centrifugation method and our modified thaw‐siphon method (Bokutoh‐siphon method; B method). The two different CRYOs extracted were analyzed to compare the differences in the amount of fibrinogen recovered, clotting factors extracted, and clotting activity. Results The amount of fibrinogen in the CRYO extracted using the B‐siphon method was similar to that obtained using the standard method (recovery of fibrinogen: B‐siphon method: 71.2% vs. standard method: 61.0%). The amount of clotting XIII factor extracted using the B‐siphon method was significantly lower than those extracted using the standard method. On the other hand, clotting II, V factors, and C1q esterase inhibitor not concentrated in CRYO content from the B‐siphon method were significantly higher than that from the standard method. Conclusion A new in‐house CRYO preparation method was established by modifying a previously used thaw‐siphon method. A coagulation factor‐rich CRYO was extracted from plasma frozen at −40°C along with the first fraction of thawed plasma, without using a large‐capacity refrigerated centrifuge for blood bags.

show abstract

Section: Methodsmentioning

confidence: 99%

“…In this study, we modified a thaw-siphon method for CRYO production from the perspective of fibrinogen recovery and showed that the modified thaw-siphon CRYO preparation, named the B (Bokutoh)-siphon method, is not inferior to the standard method originally used. 1…”

Section: Introductionmentioning

confidence: 99%

A novel modified thaw‐siphon method for extracting cryoprecipitate: The Bokutoh‐siphon method

et al. 2021

View full text Add to dashboard Cite

show abstract

“…In this study, cryoprecipitate was produced by our staff from the Department of Transfusion Medicine using a modified method as previously described. 14) In brief, one pack of cryoprecipitate was prepared from type AB RhD-positive FFP (480 mL) by collecting the precipitate formed during controlled thawing at 4°C and re-suspending in 30–50 mL plasma. The cryoprecipitate can be stored up to a year at temperatures of −20°C or lower.…”

Section: Methodsmentioning

confidence: 99%

Initial Results of Empirical Cryoprecipitate Transfusion in the Treatment of Isolated Severe Traumatic Brain Injury: Use of In-house-produced Cryoprecipitate

Shibahashi

Nishimura

Sugiyama

et al. 2019

Neurol. Med. Chir.(Tokyo)

View full text Add to dashboard Cite

Acute coagulopathy is common after traumatic brain injury (TBI), particularly in severe cases of acute subdural hemorrhage (ASDH). Although acute coagulopathy is associated with poor outcomes, the optimal treatment strategy remains unknown. Here, we report the initial results of an empirical cryoprecipitate transfusion strategy that we developed as an early intervention for acute coagulopathy after TBI. We performed chart reviews of adult patients (aged ≥18 years) who received early cryoprecipitate transfusion after admission to our institution with a diagnosis of severe TBI (Glasgow Coma Scale ≤8) and ASDH from March 2013 to December 2016. We compared the outcomes of these patients with those who were treated before the implementation of the cryoprecipitate transfusion strategy (January 2011–February 2013). During the study period, 33 patients received early cryoprecipitate transfusion and no acute transfusion-related adverse event was reported. The rate of coagulopathy development within 24 h after admission was lower in these patients (23%) than in the controls (49%), but the difference was not significant (P = 0.062). The in-hospital mortality rate was 36% in patients receiving early cryoprecipitate transfusion and 52% in controls. After adjusting for confounding factors, the in-hospital mortality rate was significantly lower in the intervention period [adjusted odds ratio: 0.25, 95% confidence interval (CI): 0.08–0.78, P = 0.017]. In summary, we analyzed initial results of a cryoprecipitate transfusion strategy in patients with severe isolated TBI and ASDH. No acute transfusion-related adverse event was observed, and early transfusion of the in-house-produced cryoprecipitate may have reduced rates of coagulopathy development and in-hospital mortality.

show abstract

“…Since CRYO is not supplied by the Japan Red Cross Society, CRYO was pre-Open Journal of Blood Diseases pared and produced by staff of our Department of Transfusion Medicine, using a modified method as previously described [8]. Briefly, one pack of CRYO was prepared from type AB RhD-positive FFP (480 mL) by collecting the precipitate formed during controlled thawing at 4˚C for 24 hours and re-suspending it in 30 -50 mL of plasma.…”

Section: In-house Cryo and Blood Productsmentioning

confidence: 99%

“…However, CRYO is neither produced nor supplied by the Japanese Red Cross Society. In-house CRYO is produced in our hospital using a method described by the Japan Society of Transfusion Medicine and Cell Therapy [8]. Therefore, we aimed to evaluate the feasibility of our transfusion practice of producing in-house CRYO for the patients with severe upper GI bleeding.…”

Section: Introductionmentioning

confidence: 99%

Evaluation of a Possible Effect of In-House Cryoprecipitate Transfusion on Outcome of Severe Upper Gastrointestinal Bleeding: A Retrospective Cohort Study

Fujita¹,

Nishimura²,

Sugiyama³

2019

OJBD

View full text Add to dashboard Cite

Purposes: Hypofibrinogenemia is usually complicated with severe and massive upper gastrointestinal (GI) bleeding, especially in liver cirrhosis. In Japan, neither fibrinogen concentrate nor cryoprecipitate (CRYO) is available for cases of acquired hypofibrinogenemia to recover the hemostatic level of fibrinogen rapidly. We prepared and produced in-house CRYO from fresh frozen plasma, and compared mortality between pre-implementation and post-implementation of CRYO. Methods: We performed a retrospective cohort study of patients admitted to our single tertiary medical center with upper GI bleeding from , we implemented the transfusion of CRYO, which was prepared and produced in our hospital. Clinical outcomes were compared between the patients in the two periods. Patients: Eleven patients in the control period and 10 in the intervention period were eligible for analysis. Results:In-hospital mortality (55% vs. 20%, P = 0.238) and mortality within 24 hour after admission (27% vs. 0%, P = 0.246) tended to be lower in the intervention period than in the control period, although the patients had more severe coagulation on admission than those in the control period. The plasma fibrinogen level before the treatment of hemostasis in the intervention period was higher than that in the control period (80 ± 9 mg/dL vs. 127 ± 15 mg/dL, P < 0.05). Conclusion: Implementation of in-house CRYO transfusion may reduce the rate of mortality due to severe upper GI bleeding.

show abstract

Protocol for the in-House Production of Cryoprecipitate

Cited by 10 publications

References 11 publications

A novel modified thaw‐siphon method for extracting cryoprecipitate: The Bokutoh‐siphon method

A novel modified thaw‐siphon method for extracting cryoprecipitate: The Bokutoh‐siphon method

Initial Results of Empirical Cryoprecipitate Transfusion in the Treatment of Isolated Severe Traumatic Brain Injury: Use of In-house-produced Cryoprecipitate

Evaluation of a Possible Effect of In-House Cryoprecipitate Transfusion on Outcome of Severe Upper Gastrointestinal Bleeding: A Retrospective Cohort Study

Contact Info

Product

Resources

About